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a  b  s  t  r  a  c  t
A  recent  study  of inactivated  inﬂuenza  vaccine  (IIV)  in  children  aged  3–8  years  demonstrated  higher
efﬁcacy  against  moderate/severe  inﬂuenza.  A meta-analysis  of  all previous  published  randomized  clinical
trials  of live  attenuated  inﬂuenza  vaccine  (LAIV)  that  collected  information  on illness  severity  in children
aged  24–71  months  was  conducted.  Moderate/severe  inﬂuenza  was  deﬁned  as fever  >39 ◦C, acute  otitis
media,  or  lower  respiratory  tract illness;  other  cases  were  classiﬁed  as milder  inﬂuenza.  LAIV  efﬁcacyeywords:
nﬂuenza
isease severity
ive attenuated inﬂuenza vaccine
versus  placebo  was  95.4%  [95%  conﬁdence  interval:  88.5,  98.1]  (year  1)  and  88.5%  [77.4,  94.9]  (year  2)
against  moderate/severe  inﬂuenza  and 91.4%  [77.9, 96.7]  (year  1) and  84.2%  [56.7,  94.3]  (year  2)  against
milder  inﬂuenza.  The  relative  efﬁcacy  of  LAIV  versus  IIV  was  52.2%  [31.6,  66.6] for moderate/severe
inﬂuenza  and 45.0%  [28.6,  57.5] for milder  inﬂuenza.  Efﬁcacy  against  all inﬂuenza  illnesses,  regardless  of
severity,  is critical  to  prevent  inﬂuenza  illness  and transmission  in the  community.
ublis©  2014  The  Authors.  P
. Introduction
Due to the high rate of inﬂuenza infection in children and the
vailability of safe and effective vaccines [1–5], the US Centers for
isease Control and Prevention recommends inﬂuenza vaccina-
ion for all children 6 months and older for their own  protection
6]. A study by Public Health England researchers that also took
nto account the role of children in the transmission of inﬂuenza
oncluded that the most efﬁcient use of vaccines to reduce overall
nﬂuenza morbidity and mortality in England and Wales is to target
hildren in addition to older adults [7].
The efﬁcacy of inﬂuenza vaccines has traditionally been assessed
gainst symptomatic laboratory-conﬁrmed inﬂuenza illnesses
ithout speciﬁc consideration of disease severity. However, a
ecently published efﬁcacy study of inactivated inﬂuenza vaccine
IIV) versus placebo in children 3–8 years of age evaluated vaccine
fﬁcacy as a function of inﬂuenza severity [8]. The per-protocol
fﬁcacy of IIV was 55% against all laboratory-conﬁrmed cases
f inﬂuenza. Efﬁcacy was higher (74%) against moderate/severe
ases due to increased efﬁcacy against moderate/severe inﬂuenza A
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disease; efﬁcacy was lower (42%; author personal communication)
against milder inﬂuenza B and inﬂuenza A illnesses. Moder-
ate/severe illnesses were those associated with the presence of
fever >39 ◦C, acute otitis media, or lower respiratory tract illness.
The efﬁcacy of live attenuated inﬂuenza virus (LAIV) in children
has been documented in several clinical trials [9], but has not been
assessed with regard to disease severity. The purpose of this study
was to evaluate the efﬁcacy of LAIV against moderate/severe and
milder laboratory-conﬁrmed inﬂuenza in children ≥24 months of
age.
2. Materials and methods
2.1. Clinical studies
All randomized clinical trials that evaluated the efﬁcacy of
LAIV in children aged 2–17 years were reviewed: two  previously
published prospective, double-blind, randomized clinical trials
comparing the efﬁcacy of LAIV versus placebo or IIV in children
collected data regarding inﬂuenza illness severity [10–12].
Study 1 was  a two-year placebo-controlled study conducted in
the United States in healthy children 15–71 months of age [11,12].
Subjects were randomly assigned in a 2:1 ratio to receive LAIV or
placebo. In year 1, subjects received LAIV or placebo as a single
dose or 2 doses administered approximately 60 days apart [11]. In
year 2, subjects received 1 dose of LAIV or placebo according to the
randomization schedule in year 1 [12].
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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Fig. 1. Efﬁcacy of LAIV compared with placebo. (A) Study 1, year 1, moderate/severe
and  mild inﬂuenza illness; (B) Study 1, year 2, moderate/severe and mild inﬂuenzaC.S. Ambrose et al. / Va
Study 2 was a one-year IIV-controlled study. Healthy children
–59 months of age in the United States, Europe, and Asia were
andomly assigned in a 1:1 ratio to receive either LAIV or IIV [10].
accine-naive children were administered two doses of vaccine
ithin a 42-day period; children who had been vaccinated pre-
iously received one dose.
LAIV consisted of 106.5–7.5 median tissue culture infectious doses
TCID50) or ﬂuorescent focus units of each of the three inﬂuenza
trains (A/H1N1, A/H3N2, and B) contained in the vaccine. The IIV-
ontrolled study used IIV manufactured by Aventis Pasteur in the
orresponding region; children 6 months to <36 months of age
eceived 0.25 mL  per dose (7.5 g of each hemagglutinin) while
hildren ≥36 months of age received 0.5 mL  per dose (15 g of
ach hemagglutinin). The characteristics of all vaccines have been
reviously reported [10–12]. Both studies were conducted in accor-
ance with the Code of Ethics of the World Medical Association
Declaration of Helsinki).
.2. Efﬁcacy endpoints
Parents or guardians recorded daily temperatures and signs or
ymptoms of respiratory illness and were instructed to promptly
otify study personnel if their child developed qualifying symp-
oms. They were also contacted every 7–10 days throughout the
nﬂuenza season.
Nasal swabs were collected if a child had ≥1 of the following:
cute otitis media (suspected or diagnosed), fever, pneumonia, pul-
onary congestion, shortness of breath, or wheezing, or ≥2 of the
ollowing symptoms concurrently: chills, cough, decreased activ-
ty, headache, irritability, muscle aches, pharyngitis, rhinorrhea, or
omiting. Central laboratories evaluated nasal swabs for the pres-
nce of inﬂuenza virus by viral culture; wild-type serotypes were
dentiﬁed using antigenic methods.
Laboratory-conﬁrmed cases of inﬂuenza were classiﬁed as mod-
rate/severe inﬂuenza if there was any documentation of fever
39 ◦C, acute otitis media, or lower respiratory tract illness (deﬁned
s healthcare provider-conﬁrmed shortness of breath, pulmonary
ongestion, pneumonia, bronchiolitis, bronchitis, wheezing, or
roup). All other cases were classiﬁed as milder inﬂuenza.
.3. Statistical analysis
All children ≥24 months of age were retained in this post hoc
nalysis. Efﬁcacy was calculated as one minus the relative risk of
aboratory-conﬁrmed inﬂuenza regardless of antigenic match with
AIV versus placebo or IIV. Efﬁcacy was evaluated ﬁrst against mod-
rate/severe cases of inﬂuenza in all children, then against mild
ases of inﬂuenza only. The 95% CIs of the vaccine efﬁcacy point esti-
ates were obtained by a log-binomial regression. Results from the
wo studies were not combined because study 1 assessed LAIV efﬁ-
acy versus placebo, whereas study 2 assessed LAIV efﬁcacy versus
IV.
. Results
A total of 1330 children ≥24 months of age in year 1 (LAIV,
 = 897; placebo, n = 433) and 1358 children in year 2 (LAIV, n = 917;
lacebo, n = 441) were enrolled in study 1. The attack rates of mod-
rate/severe inﬂuenza were 0.6% (5/897) in year 1 and 1.1% (10/917)
n year 2 in the LAIV group versus 12.0% (52/433) in year 1 and
.5% (42/441) in year 2 in the placebo group, resulting in efﬁcacy
stimates of 95.4% (95% CI: 88.5, 98.1) in year 1 and 88.5% (77.4,
4.9) in year 2 (Figs. 1A and 1B). The attack rates of mild inﬂuenza
ere 0.6% (5/892) in year 1 and 0.6% (5/907) in year 2 in the LAIV
roup versus 6.6% (25/381) in year 1 and 3.6% (14/399) in year
 in the placebo group, resulting in efﬁcacy estimates of 91.4%illness; (C) Study 2: relative efﬁcacy of LAIV compared with IIV. IIV = inactivated
inﬂuenza vaccine; LAIV = live attenuated inﬂuenza vaccine.
(77.9, 96.7) and 84.2% (56.7, 94.3) in year 1 and year 2, respectively
(Figs. 1A and 1B). In year 1, both A/H3N2 and B strains circu-
lated. Efﬁcacy against moderate/severe inﬂuenza for A/H3N2 and B
strains was  95.7% (86.5, 99.2) and 95.8% (83.0, 99.5), respectively.
Efﬁcacy against mild inﬂuenza for A/H3N2 and B strains was  94.3%
(76.1, 99.4) and 83.9% (35.5, 97.2), respectively.
Study 2 enrolled a total of 4166 children ≥24 months of age
(LAIV, n = 2083; placebo, n = 2083). The attack rate of moder-
ate/severe inﬂuenza was  2.1% (43/2083) in the LAIV group versus
4.3% (90/2083) in the IIV group, resulting in a relative efﬁcacy of
LAIV compared with IIV of 52.2% (31.6, 66.6). The attack rate of mild
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nﬂuenza, after exclusion of moderate or severe cases, was 4.1%
84/2040) in the LAIV group versus 7.5% (149/1993) in the placebo
roup, resulting in a relative efﬁcacy of 45.0% (28.6, 57.5) (Fig. 1C).
fﬁcacy against moderate/severe inﬂuenza for A/H1N1, A/H3N2,
nd B was 100% (−9.1, 100), 80.9 (60.5, 91.7), and 10.3 (−45.4, 44.8),
espectively. Efﬁcacy against mild inﬂuenza for A/H1N1, A/H3N2,
nd B was 91.7% (66.4, 99.0), 59.1% (35.1, 74.9), and 13.6% (−25.0,
0.5).
. Discussion
Children are considered a priority group for vaccination because
f the high burden of inﬂuenza disease among children and the
vailability of safe and effective vaccines. Vaccinating children
gainst inﬂuenza also can indirectly protect other age groups
gainst inﬂuenza. Public health agencies promote vaccination
gainst inﬂuenza in children because they have been identiﬁed as
he main spreaders of inﬂuenza infection [7]. From this perspec-
ive, it is important to prevent any inﬂuenza case, independent of
isease severity. To best characterize a vaccine’s effect on inﬂuenza
ransmission, inﬂuenza vaccine efﬁcacy should be assessed against
ll shedding inﬂuenza infections, whether severe or mild, symp-
omatic or not [13].
Although several clinical trials have documented the efﬁcacy of
AIV in children [9], this study is the ﬁrst evaluation of LAIV efﬁ-
acy as a function of disease severity. LAIV was efﬁcacious against
oderate/severe inﬂuenza and against milder inﬂuenza. LAIV was
lso signiﬁcantly more efﬁcacious than IIV for inﬂuenza A dis-
ase of all severity levels. The lack of LAIV superiority relative to
IV for inﬂuenza B in the current analysis may  be due to the fact
hat a signiﬁcant proportion of inﬂuenza B cases were due to anti-
enic variant strains. Two other IIV-controlled studies of LAIV in
hildren demonstrated LAIV superiority against matched B strains
14,15]; however, neither of these studies collected data on disease
everity.
Together with the recent study demonstrating high levels of
IV efﬁcacy only against moderate/severe inﬂuenza A disease, the
esults of this analysis show that LAIV provides children with a high
egree of protection against inﬂuenza A and B illness of all sever-
ty levels and thus should be effective in interrupting inﬂuenza
ransmission by children in the community. These differences in
he efﬁcacy of IIV and LAIV in children may  be due to the dif-
erential mechanisms of action of the two vaccines, with LAIV
roviding a robust mucosal immune responses and IIV provid-
ng a predominantly systemic response; a more robust mucosal
mmune response could be more effective against more mild infec-
ions [16–18].
A limitation of this analysis is that we could not investigate vac-
ine efﬁcacy against asymptomatic inﬂuenza infections. However,
AIV efﬁcacy estimates remained stable for moderate/severe and
ild inﬂuenza illness; the point estimates for efﬁcacy against mild
nﬂuenza were always contained within the 95% conﬁdence inter-
als of the efﬁcacy estimates against moderate/severe inﬂuenza.
hese results also suggest that LAIV might also be similarly efﬁca-
ious against asymptomatic inﬂuenza infections.
In summary, LAIV provided consistently high efﬁcacy against
oderate/severe and milder inﬂuenza illness compared with
lacebo in children >24 months of age. It also was consistently
ore efﬁcacious than IIV. Efﬁcacy against all inﬂuenza illnesses,
egardless of severity, is critical to prevent inﬂuenza illness and
ransmission in the community.
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